Stock YMAB Y-MABS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:57:03 2024-04-23 am EDT 		5-day change 1st Jan Change
16.26 USD +7.26% Intraday chart for Y-mAbs Therapeutics, Inc. +5.75% +134.75%
Mar. 14 Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign MT
Mar. 14 Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024 CI

Business Summary

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Number of employees: 100

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Antibody-based Therapeutic Products
100.0 %
49 100.0 % 84 100.0 % +71.15%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
80.4 %
46 93.9 % 68 80.4 % +46.60%
Other Countries
19.6 %
3 6.1 % 17 19.6 % +448.70%

Managers

Managers TitleAgeSince
Thomas Gad FOU
 Founder 54 15-03-31
Michael Rossi CEO
 Chief Executive Officer 53 Nov. 05
Bo Kruse DFI
 Director of Finance/CFO 52 16-05-31
Vignesh Rajah CTO
 Chief Tech/Sci/R&D Officer 59 20-05-31
Joris Wilms COO
 Chief Operating Officer 50 17-10-31
Torben Lund-Hansen CTO
 Chief Tech/Sci/R&D Officer 73 15-12-31
Sue Smith PRN
 Corporate Officer/Principal 54 -

Members of the board

Members of the board TitleAgeSince
David Gill BRD
 Director/Board Member 69 17-11-30
Johan Ernst Wedell-Wedellsborg BRD
 Director/Board Member 54 15-08-31
James Healy CHM
 Chairman 58 17-10-31
Ashutosh Tyagi BRD
 Director/Board Member 47 17-10-31
Bo Kruse DFI
 Director of Finance/CFO 52 16-05-31
Gérard Ber BRD
 Director/Board Member 66 18-12-10
Michael Rossi CEO
 Chief Executive Officer 53 Nov. 05
Thomas Gad FOU
 Founder 54 15-03-31
Laura Hamill BRD
 Director/Board Member 60 20-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 43,777,105 37,409,819 ( 85.46 %) 0 85.46 %

Shareholders

NameEquities%Valuation
Johan Ernst Wedell-Wedellsborg
10.41 %
4,559,233 10.41 % 74 M $
HBM Partners AG (Investment Management)
7.533 %
3,297,800 7.533 % 54 M $
Acorn Capital Advisors LLC
6.309 %
2,761,825 6.309 % 45 M $
BlackRock Advisors LLC
6.126 %
2,681,727 6.126 % 44 M $
Vanguard Fiduciary Trust Co.
5.127 %
2,244,238 5.127 % 36 M $
Paradigm BioCapital Advisors LP
5.022 %
2,198,312 5.022 % 36 M $
Sofinnova Investments, Inc.
5.012 %
2,194,278 5.012 % 36 M $
POLAR CAPITAL HOLDINGS PLC
4.699 %
2,056,872 4.699 % 33 M $
D.E. Shaw & Co., Inc.
3.024 %
1,323,780 3.024 % 22 M $
Caligan Partners LP
2.395 %
1,048,425 2.395 % 17 M $

Company contact information

Y-mAbs Therapeutics, Inc.

230 Park Avenue Suite 3350

10169-0005, New York

+

http://www.ymabs.com
address Y-mAbs Therapeutics, Inc.(YMAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Y-mAbs Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.16 USD
Average target price
21.67 USD
Spread / Average Target
+42.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
Y-MABS THERAPEUTICS, INC. Stock Y-mAbs Therapeutics, Inc.
+122.29% 664M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.71% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.49% 96.73B
ARGENX SE Stock argenx SE
+1.37% 21.31B
BIONTECH SE Stock BioNTech SE
-16.61% 21.21B
GENMAB A/S Stock Genmab A/S
-6.73% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.14% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.40% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.44% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.29% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. YMAB Stock
  4. Company Y-mAbs Therapeutics, Inc.